Expanding Large Molecule Capabilities: Teva#8217;s Latest Acquisition

By Business Review Editor

Pharma Deals Review: Vol 2008 Issue 93 (Table of Contents)

Published: 1 Mar-2008

DOI: 10.3833/pdr.v2008.i93.207     ISSN: 1756-7874

Section: Features



The desire of generics companies to diversify into the biologics arena has been demonstrated in the recent US$400 M acquisition of CoGenesys by the Israeli generics giant, Teva Pharmaceutical Industries...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details